N-Boc-4-哌啶丙酸乙酯 | 301232-45-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-Boc-4-哌啶丙酸乙酯
• 中文别名: N-BOC-4-哌啶丙酸乙酯；4-(3-乙氧基-3-氧代丙基)哌啶-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate
• CAS: 301232-45-1
• 化学式: C₁₅H₂₇NO₄
• 分子量: 285.384
• InChiKey: LOMUFJYCJDQUID-UHFFFAOYSA-N

物化性质

• 密度：
  1.036

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-(N-BOC-piperidin-4-yl)propioate
Synonyms: tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-(N-BOC-piperidin-4-yl)propioate
CAS number: 301232-45-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H27NO4
Molecular weight: 285.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-4-哌啶丙酸乙酯 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 以97.2 %的产率得到3-哌啶-4-丙酸乙酯
  参考文献：
  名称：

  [EN] HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF
  [FR] COMPOSÉ CYCLIQUE HÉTÉROAROMATIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 杂芳环化合物、其制备方法及用途

  摘要：

  本发明涉及杂芳环化合物、其制备方法及用途。具体而言，本发明涉及式(I)的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，包含其的药物组合物，其制备方法及其在制备用于预防或治疗KRAS G12D介导的相关疾病的药物中的用途。

  公开号：

  WO2024001839A1
• 作为产物：
  描述：

  N-叔丁氧羰基-(2-乙氧羰基-乙烯基)-哌啶) 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 N-Boc-4-哌啶丙酸乙酯
  参考文献：
  名称：

  具有（2R）-2-[（（1R）-3,3-二氟环戊基] -2-羟基苯基乙酰胺结构的毒蕈碱M（3）受体拮抗剂。第2部分。

  摘要：

  进行了我们原始毒蕈碱型M（3）受体拮抗剂1的胺部分的优化，以鉴定出优于1的M（3）受体拮抗剂。对氮原子上带有疏水取代基的各种二胺部分的化合物进行了筛选。 M（3）受体的结合亲和力和M（3）超过M（1）和M（2）受体的选择性。该过程导致了4-氨基哌啶酰胺（2l），其K（i）值为5.1 nM，M（3）受体的选择性比M（2）受体大46倍。通过插入间隔基或将烷基引入胺部分进一步2l衍生化，从而鉴定出K（i）值为3的4-（氨基乙基）哌啶酰胺2l-b。

  DOI：

  10.1016/s0960-894x(03)00350-0

文献信息

• One-Pot, Tandem Wittig Hydrogenation: Formal C(sp³)–C(sp³) Bond Formation with Extensive Scope
  作者：Rory Devlin、David J. Jones、Gerard P. McGlacken

  DOI：10.1021/acs.orglett.0c01874

  日期：2020.7.2

  A one-pot, tandem Wittig hydrogenation of aldehydes with stabilized ylides is reported, representing a formal C(sp3)–C(sp3) bond construction. The tandem reaction operates under mild conditions, is high yielding, and is broad in scope. Chemoselectivity for olefin reduction is observed, and the methodology is demonstrated in the synthesis of lapatinib analogues and a formal synthesis of (±)-cuspareine

  据报道，用稳定的乙炔对一锅进行串联的Wittig醛加氢反应，代表了正式的C（sp 3）–C（sp 3）键结构。串联反应在温和条件下进行，收率高，适用范围广。观察到对烯烃还原的化学选择性，并且该方法在拉帕替尼类似物的合成和（±）-cuspareine的正式合成中得到了证明。早期的见解表明，在还原步骤中观察到的化学选择性是由于在步骤1之后催化剂部分中毒所致，因此增加了一锅法的能力。
• Electrochemical Tandem Olefination and Hydrogenation Reaction with Ammonia
  作者：Xiaofeng Zhang、Runze Jiang、Xu Cheng

  DOI：10.1021/acs.joc.1c01024

  日期：2021.11.19

  Horner–Wadsworth–Emmons/hydrogenation tandem reaction was achieved using ammonia as electron and proton donors. The reaction could give two-carbon-elongated ester and nitrile from aldehyde or ketones directly. This reaction could proceed with a catalytic amount of base or even without a base. The ammonia provides both the electron and proton for this tandem reaction and enables the catalyst-free hydrogenation

  使用氨作为电子和质子供体实现了电化学 Horner-Wadsworth-Emmons/氢化串联反应。该反应可以直接由醛或酮得到双碳延伸的酯和腈。该反应可以在催化量的碱或什至没有碱的情况下进行。氨为该串联反应提供电子和质子，并使 α,β-不饱和 HWE 中间体的无催化剂氢化成为可能。报告了 40 多个例子，并且可以容忍包括杂环和羟基在内的官能团。
• N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
  申请人：——

  公开号：US20040002504A1

  公开（公告）日：2004-01-01

  The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: 1 wherein, generally, Q is 2 R 1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C 1-4 alkyl or halogen, such as methyl, fluorine or bromine; R 2 is hydrogen or C 1-4 alkyl such as methyl; R 3 is phenyl; R 4 is hydrogen; R 5 is hydrogen or C 1-6 alkylcarbonyl such as methylcarbonyl; X is —SO 2 — or —C(O)N(R 2 )SO 2 — where R 2 is preferably hydrogen; Y is a bond, CH 2 or Z 1 where Z 1 is —N(R f )— in which R f is C 1-6 alkylcarbonyl such as ethylcarbonyl; and R 6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C 1-6 alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗患有疾病（如精神分裂症）的受试者的方法，其中该疾病的治疗需要使用NK-3拮抗剂，包括向该受试者施用化合物I的治疗有效量： 1 其中，通常情况下， Q是 2 R 1 是苄基、苯基、噻吩或咪唑基，可选择地用C 1-4 烷基或卤素（如甲基、氟或溴）取代； R 2 是氢或C 1-4 烷基，如甲基； R 3 是苯基； R 4 是氢； R 5 是氢或C 1-6 烷基羰基，如甲基羰基； X是—SO 2 —或—C(O)N(R 2 )SO 2 —，其中R 2 最好是氢； Y是键、CH 2 或Z 1 ，其中Z 1 是—N(R f )—，其中R f 是C 1-6 烷基羰基，如乙基羰基；以及 R 6 是苯基、吡唑基、吡啶基、嘧啶基或苯并咪唑基，可选择地用来自C 1-6 烷基和苄基的一个或两个基团取代，如甲基、乙基和苄基； 或其药学上可接受的盐。
• Ester derivatives
  申请人：——

  公开号：US20030191316A1

  公开（公告）日：2003-10-09

  This invention relates to compounds which exhibit selective muscarinic M 3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); 1 [in which A signifies a group expressed by a formula (a 0 ) or (b 0 ); 2 Ar signifies optionally substituted aryl or heteroaryl; B 1 and B 2 signify aliphatic hydrocarbon; R 1 signifies fluorine-substituted cycloalkyl; R 2 , R 3 and R 4 signify lower alkyl, single bond or alkylene bonded to B 1 , or R 2 and R 3 are united to signify alkylene; R 5 and R 7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B 2 ; R 6 signifies hydrogen, lower alkyl or a group expressed as —N(R 8 )R 9 ; and X − signifies an anion].

  这项发明涉及表现出选择性肌肉M3受体拮抗作用、副作用小、适用于吸入疗法并且可用作治疗呼吸系统疾病的治疗剂的化合物，其一般式为（I）； 其中A表示由式（a0）或（b0）表示的基团； Ar表示可选择取代的芳基或杂环芳基；B1和B2表示脂肪烃基；R1表示氟取代的环烷基；R2、R3和R4表示较低的烷基、与B1结合的单键或烷基，或者R2和R3结合表示烷基；R5和R7表示氢、较低的烷基，或者与B2结合的单键或烷基；R6表示氢、较低的烷基或表示为—N(R8)R9的基团；X-表示阴离子。
• SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS
  申请人：DeMong E. Duane

  公开号：US20070197590A1

  公开（公告）日：2007-08-23

  Substituted dipiperidine compounds of Formula (I) or a form thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula (I)中的取代二哌啶化合物或其形式，它们是CCR2拮抗剂，可用于预防、治疗或改善需要的主体中的CCR2介导的炎症综合征、紊乱或疾病。